© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
April 08, 2021
In patients who received early palliative care, researchers noted a lower percentage of patients with depression, improved quality of life, and, significantly, longer survival.
March 19, 2021
Language barriers can present a major obstacle to patient involvement in cancer care, although clinicians recommended several potential strategies to help patients who speak different languages.
March 15, 2021
A viewpoint perspective from 3 experts endorsed the requirement for a patient and their physician to engage in a shared discussion of benefits and harms before proceeding with a low-dose spiral computed tomography (LDCT) scan in order to prevent lung cancer death.
March 12, 2021
The FDA announced that it will hold a public meeting of the Oncologic Drugs Advisory Committee from April 27 to 29 to address the indications granted accelerated approval for 6 therapies.
The FDA has granted a fast track designation to poziotinib for use in previously treated non-small cell lung cancer patients with HER2 exon 20 mutations.
March 10, 2021
The VENTANA ALK CDx assay is a companion diagnostic to identify patients with ALK-positive non–small cell lung cancer who are eligible to receive treatment with lorlatinib.
February 23, 2021
This is the third approval for Libtayo, following approvals as the first immunotherapy for patients with advanced basal cell carcinoma and as the first systemic treatment for advanced cutaneous squamous cell carcinoma.
February 22, 2021
As a direct result of the global pandemic, the landscape for oncology health care professionals has changed.
February 17, 2021
A recent comprehensive, prospective study of smoking habits among patients with non-small cell lung cancer demonstrated a high rate of smoking reduction and cessation following entry into the phase 3 early-stage trial.
The FDA has granted priority review to sotorasib for the treatment of patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer, after at least 1 previous systemic therapy.